More than 10% of these “mis-expressed” genes were identified previously as up-regulated by DNMT1 inhibition in ADRN NB (Henrich et al, 2016), suggesting that epigenetic drugs (DNMT- and EZH2 inhibitors) warrant further evaluation in the context of kalirin–GEF1–inhibited ADRN-type cells. This evidence concerns the gene EZH2 and neuroblastoma.